Enfusion Inc (NYSE: ENFN) has a higher price-to-earnings ratio of 382.44x compared to its average ratio, The 36-month beta value for ENFN is at 0.99. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 as “hold,” and 3 as “sell.”
The public float for ENFN is 50.08M, and currently, shorts hold a 2.03% of that float. The average trading volume for ENFN on November 28, 2024 was 403.33K shares.
ENFN) stock’s latest price update
The stock of Enfusion Inc (NYSE: ENFN) has decreased by -1.09 when compared to last closing price of 10.13.Despite this, the company has seen a gain of 1.31% in its stock price over the last five trading days. businesswire.com reported 2024-11-20 that NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion’s Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: Wells Fargo 8th Annual TMT Summit on Tuesday, December 3, 2024 UBS Global Technology and AI Conference on Wednesday, December 4, 2024 Live audio webcasts and ar.
ENFN’s Market Performance
ENFN’s stock has risen by 1.31% in the past week, with a monthly rise of 8.32% and a quarterly rise of 22.20%. The volatility ratio for the week is 3.08% while the volatility levels for the last 30 days are 3.53% for Enfusion Inc The simple moving average for the last 20 days is 4.40% for ENFN’s stock, with a simple moving average of 11.51% for the last 200 days.
Analysts’ Opinion of ENFN
Many brokerage firms have already submitted their reports for ENFN stocks, with Morgan Stanley repeating the rating for ENFN by listing it as a “Overweight.” The predicted price for ENFN in the upcoming period, according to Morgan Stanley is $11 based on the research report published on May 10, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ENFN reach a price target of $8, previously predicting the price at $9. The rating they have provided for ENFN stocks is “Sell” according to the report published on February 28th, 2024.
JP Morgan gave a rating of “Underweight” to ENFN, setting the target price at $9 in the report published on January 30th of the current year.
ENFN Trading at 8.06% from the 50-Day Moving Average
After a stumble in the market that brought ENFN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.11% of loss for the given period.
Volatility was left at 3.53%, however, over the last 30 days, the volatility rate increased by 3.08%, as shares surge +11.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.00% upper at present.
During the last 5 trading sessions, ENFN rose by +1.31%, which changed the moving average for the period of 200-days by +17.88% in comparison to the 20-day moving average, which settled at $9.60. In addition, Enfusion Inc saw 3.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENFN starting from Campobasso Matthew, who sale 674 shares at the price of $8.95 back on Oct 22 ’24. After this action, Campobasso Matthew now owns 53,627 shares of Enfusion Inc, valued at $6,032 using the latest closing price.
Campobasso Matthew, the Officer of Enfusion Inc, proposed sale 674 shares at $8.95 during a trade that took place back on Oct 22 ’24, which means that Campobasso Matthew is holding shares at $6,031 based on the most recent closing price.
Stock Fundamentals for ENFN
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.67 for the gross margin
The net margin for Enfusion Inc stands at 0.02. The total capital return value is set at 0.06. Equity return is now at value 5.54, with 2.82 for asset returns.
Based on Enfusion Inc (ENFN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 5.13. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 22.13.
Currently, EBITDA for the company is 21.93 million with net debt to EBITDA at -1.54. When we switch over and look at the enterprise to sales, we see a ratio of 4.71. The receivables turnover for the company is 6.07for trailing twelve months and the total asset turnover is 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In conclusion, Enfusion Inc (ENFN) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.